Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Myriad is a leading molecular diagnostic company focused on predictive, personalized, and prognostic medicine. The company operates two segments: Genetics (corporate services and gene discovery) and Molecular Diagnostics (testing services). Following a spin-off on June 30, 2009, the company's former research and drug development businesses are reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2010 | Nine Months Ended Mar 31, 2010 |
|---|---|---|
| Revenue | $90,830 | $268,720 |
| Cost of Revenue | $10,880 | $33,024 |
| Gross Margin | 88% | 88% |
| Operating Income | $33,225 | $97,460 |
| Net Income | $33,251 | $99,053 |
| Diluted EPS | $0.33 | $1.00 |
| Cash and Cash Equivalents | $102,149 | $102,149 (Balance Sheet) |
| Total Marketable Securities | $409,034 | $409,034 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $108,564 |
| Debt | $0 | $0 |
Note: Total Marketable Securities includes $296,500 current and $112,534 long-term.
Material Changes vs. Prior Period
- Revenue Growth: Molecular diagnostic revenue increased 5% year-over-year for the quarter ($90.8M vs. $86.5M) and 12% for the nine-month period ($268.7M vs. $240.4M), driven by increased testing volume and market penetration.
- Profitability: Net income for the nine months ended March 31, 2010, was $99.1 million, a significant increase from $61.0 million in the prior year period. This improvement is largely due to the absence of losses from discontinued operations (research and drug development) which were spun off in June 2009.
- Expense Increases:
- R&D: Increased 30% for the quarter and 23% for the nine months due to clinical studies and product development.
- Selling, General, and Administrative (SG&A): Increased 15% for the quarter and 18% for the nine months, primarily due to expanded sales/marketing efforts (including direct-to-consumer campaigns) and higher share-based compensation.
- Interest Income: Decreased 58% for the quarter and 52% for the nine months due to lower interest rates and the prior year's contribution of $188 million in cash/securities to the spun-off entity (MPI).
Guidance, Outlook, and Risks
- Product Pipeline: Management expects to launch a ninth molecular diagnostic product for pancreatic cancer predisposition in the second half of calendar 2010.
- Capital Allocation: On May 4, 2010, the Board authorized a $100 million share repurchase program, expected to be completed by December 31, 2010.
- Liquidity: The company maintains strong liquidity with over $511 million in cash and marketable securities. Management believes existing resources are adequate for foreseeable operations.
- Legal Proceedings (Critical): On April 19, 2010, a U.S. District Court ruled that 15 claims of seven patents related to the BRCA1 and BRCA2 genes (underlying the company's flagship BRACAnalysis product) are invalid. Myriad intends to appeal this decision to the Court of Appeals for the Federal Circuit.
- Economic Risks: Management notes that high unemployment and economic challenges may negatively impact revenue growth, as patients may delay doctor visits or lose insurance coverage.
Investor Verification Checklist
- Patent Litigation Status: Verify the progress and potential outcome of the appeal regarding the invalidation of BRCA1/BRCA2 patent claims, as this poses a material risk to the core revenue stream.
- Revenue Sustainability: Assess whether the 12% revenue growth rate is sustainable given the "one-time per patient" nature of many diagnostic tests and the current economic climate.
- Share Repurchase Execution: Monitor the execution of the $100 million share buyback program and its impact on cash reserves.
- Product Launch Timeline: Confirm the launch date and market reception of the upcoming pancreatic cancer test.
- Bad Debt Exposure: Review the allowance for doubtful accounts ($4.4 million) and the impact of economic conditions on collection rates from healthcare providers.